IDiyas

For the Inventor, By the Inventor

Ann Arbor, MI, United States of America

Christopher Franklin Bigge

USPTO Granted Patents = 28 

 

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 190(Granted Patents)


Location History:

  • Ypsilanti, MI (US) (1987)
  • Ann Arbor, MI (US) (1991 - 2008)

Company Filing History:

goldMedal18 out of 2,538 
 
Warner-lambert Company
 patents
silverMedal3 out of 18 
 
Cocensys Inc.
 patents
bronzeMedal3 out of 4,455 
 
Pfizer Corporation
 patents
4. 1 out of 206 
 
Neurosearch A/s
 patents
5. 6 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1987-2008

Loading Chart...
Loading Chart...
28 patents (USPTO):
1. 7407974 - Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade (2008-08-05),
2. 7030141 - Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade (2006-04-18),
3. 6972287 - Method of inhibiting amyloid protein aggregation and imaging amyloid deposits (2005-12-06),
4. 6949575 - Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives (2005-09-27),
5. 6703391 - Quinoxalinedione derivatives, their preparation and use (2004-03-09),
6. 6696474 - Antidiabetic agents (2004-02-24),
7. 6534525 - 2-substituted piperidine analogs and their use as subtype-selective NMDA receptor antagonists (2003-03-18),
8. 6534522 - Subtype-selective NMDA receptor ligands and the use thereof (2003-03-18),
9. 6448270 - 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists (2002-09-10),
10. 6218404 - Subtype-selective NMDA receptor ligands and the use thereof (2001-04-17),
11. 6197771 - Glutamate (ampa/kainate) receptor antagonists: N-substituted fused azacycloalkylquinoxalinediones (2001-03-06),
12. 6130234 - 4-substituted piperidine analogs and their use as subtype selective NMDA (2000-10-10),
13. 6124323 - 4-substituted piperidine analogs and their use as subtype selective NMDA (2000-09-26),
14. 6124317 - 2-substituted piperidine analogs and their use as subtype-selective NMDA (2000-09-26),
15. 6057313 - Glutamate (ampa/kainate) receptor antagonists: N-substituted fused (2000-05-02),

Title: Innovator Spotlight: Christopher Franklin Bigge

Introduction:

Christopher Franklin Bigge is a renowned inventor based in Ann Arbor, MI (US) with an impressive track record in the field of pharmaceuticals. With a total of 28 patents to his name, his contributions to the development of treatments for thrombotic disorders have significantly impacted the medical industry.

Latest Patents:

Bigge's latest patents involve the creation of inhibitors of factor Xa and other serine proteases that play a crucial role in the coagulation cascade. These compounds, as outlined in Formula (I), offer innovative solutions for treating thrombotic disorders. Additionally, the patents detail pharmaceutical compositions, preparation processes, and intermediates related to the compounds.

Career Highlights:

Throughout his career, Christopher Franklin Bigge has been associated with leading companies in the pharmaceutical sector. Some of the notable organizations he has worked with include Warner-Lambert Company, where his innovative research and developments have paved the way for groundbreaking treatments in thrombosis management.

Collaborations:

Bigge's success in the field of pharmaceutical inventions is also attributed to his collaborations with esteemed colleagues. Among them are Graham Johnson and Sui Xiong Cai, who have been instrumental in driving forward research initiatives and fostering a culture of innovation.

Conclusion:

In conclusion, Christopher Franklin Bigge's expertise as an inventor in the pharmaceutical domain is evident through his numerous patents and groundbreaking contributions to treating thrombotic disorders. His collaborations with industry peers and his tenure at esteemed companies reflect a career dedicated to advancing medical science for the betterment of society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…